Acurx Pharmaceuticals, Inc.
ACXP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $7 | $12 | $8 | $14 |
| - Cash | $5,907 | $6 | $5 | $4 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$5,900 | $6 | $3 | $10 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$2 | -$2 | $0 | $0 |
| % Margin | – | – | – | – |
| Net Income | -$2 | -$2 | -$2 | -$3 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.23 | -1.89 | -2.14 | -3.27 |
| % Growth | 34.9% | 11.7% | 34.6% | – |
| Operating Cash Flow | -$2 | -$2 | -$2 | -$2 |
| Capital Expenditures | -$0 | $0 | $0 | $0 |
| Free Cash Flow | -$2 | -$2 | -$2 | -$2 |